Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies
- 1 February 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (3) , 875-882
- https://doi.org/10.1158/1078-0432.ccr-07-1250
Abstract
Purpose: Successful radioimmunotherapy strategies depend on selecting radioisotopes with physical properties complementary to the biological properties of the targeting vehicle. Small, engineered antitumor antibody fragments are capable of rapid, highly specific tumor targeting in immunodeficient mouse models. We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived α-emitting radioisotope 211At. Experimental Design: Immunodeficient nude mice bearing established HER2/neu–positive MDA-MB-361/DYT2 tumors treated with N-succinimidyl N-(4-[211At]astatophenethyl)succinamate (211At-SAPS)-C6.5 diabody. Additional cohorts of mice were treated with 211At-SAPS T84.66 diabody targeting the carcinoembryonic antigen or 211At-SAPS on a diabody specific for the Müllerian inhibiting substance type II receptor, which is minimally expressed on this tumor cell line. Results: A single i.v. injection of 211At-SAPS C6.5 diabody led to a 30-day delay in tumor growth when a 20 μCi dose was administered and a 57-day delay in tumor growth (60% tumor-free after 1 year) when a 45 μCi dose was used. Treatment of mice bearing the same tumors with 211At-SAPS T84.66 diabody at the same doses led to a delay in tumor growth, but no complete responses, likely due to substantially lower expression of this antigen on the MDA-MB-361/DYT2 tumors. In contrast, a dose of 20 μCi of 211At-SAPS on the anti–Müllerian-inhibiting substance type II receptor diabody did not affect tumor growth rate, demonstrating specificity of the therapeutic effect. Conclusions: These findings indicate that diabody molecules can be effective agents for targeted radioimmunotherapy of solid tumors using powerful, short-lived α-emitting radioisotopes.Keywords
This publication has 31 references indexed in Scilit:
- Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancerMolecular Cancer Therapeutics, 2006
- Monoclonal antibody therapy of cancerNature Biotechnology, 2005
- Renal Tubulointerstitial Changes after Internal Irradiation with α-Particle–Emitting Actinium DaughtersJournal of the American Society of Nephrology, 2005
- Efforts to Control the Errant Products of a Targeted In vivo GeneratorCancer Research, 2005
- Preparation and in vivo evaluation of novel linkers for 211At labeling of proteinsNuclear Medicine and Biology, 2004
- A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient MiceCancer Research, 2004
- Improving monoclonal antibodies for cancer therapyDrug Development Research, 2004
- Radioimmunotherapy with engineered antibodiesExpert Opinion on Biological Therapy, 2004
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody moleculesNuclear Medicine and Biology, 2000